News

Compass Therapeutics to Reveal Financial Insights on Q2 Performance

Compass Therapeutics to Reveal Financial Insights on Q2 Performance

Upcoming Financial Results and Business Update

Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focusing on oncology, is slated to announce its financial results for the second quarter. This announcement coincides with a conference call that will provide insights into their current research efforts. The event is scheduled for Monday, August 11, and will begin at 8:00 a.m. ET.

Details of the Event

During this virtual event, Compass Therapeutics will not only discuss financial results but also share updates on pivotal projects. This includes ongoing development for tovecimig, a Phase 2/3 clinical study, along with essential data regarding CTX-8371 and CTX-10726. Investors and interested parties can anticipate a thorough review of the company’s progress.

Call Information

The call will open on August 11, 2025, at 8:00 AM ET. Participants can join via a telephone dial-in featuring two options: 1-877-407-9716 for US callers and 1-201-493-6779 for international participants. The conference ID for the call is 13754954, making it easy for individuals to connect.

Webcast Availability

A live webcast of the event will be hosted and will also be accessible for replay. This means stakeholders will have the opportunity to revisit the discussions for a limited time following the event.

Company Overview

Compass Therapeutics is committed to innovating in the field of oncology through the development of antibody-based therapeutics aimed at various diseases. Their strategic focus lies in understanding the interaction between angiogenesis, the immune system, and tumor development. The company has established a diverse pipeline of product candidates, each designed to effectively engage with critical biological pathways needed for an anti-tumor response.

Innovative Research Approach

By capitalizing on its strong foundation in scientific research, Compass aims to craft targeted therapies that include agents for angiogenesis, immune response activators, and strategies to counteract the immunosuppressive tactics used by tumors. These efforts reflect Compass Therapeutics’ commitment to clinical development that emphasizes both standalone and combinatorial therapies utilizing their proprietary pipeline antibodies.

Investor Relations

For those interested in investor relations, further inquiries can be directed to the Investor contact via email at ir@compasstherapeutics.com. Media inquiries can be made to Anna Gifford, Chief of Staff, at media@compasstherapeutics.com or by phone at 617-500-8099.

Frequently Asked Questions

What is the date of Compass Therapeutics' financial results announcement?

The financial results will be announced on August 11, 2025.

How can I participate in the conference call?

You can join the conference call by dialing 1-877-407-9716 for US participants or 1-201-493-6779 for international participants. Use conference ID 13754954.

Will there be a webcast available?

Yes, there will be a live webcast available along with a replay for a limited time post-event.

What is the main focus of Compass Therapeutics?

Compass Therapeutics focuses on developing proprietary antibody-based therapeutics for oncology, targeting multiple critical pathways relevant for treating tumors.

Who can I contact for investor relations?

For investor relations inquiries, please email ir@compasstherapeutics.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 4

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 5

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 1

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading

Top 5 Most Recently Viewed Articles

Mirion Technologies Earnings Insights: Key Metrics and Analysis

Updated Category News Views 196

Mirion Technologies Earnings Insights Ahead of Quarterly Release Mirion Technologies (NYSE: MIR) is preparing for an upcoming quarterly earnings announcement that has generated considerable attention among investors. The anticipation is palpable as analysts suggest that the company is poised to report an earnings per share (EPS) of $0.09. Understanding the implications of...

Continue Reading
Algebrik AI Unveils Innovative Advisory Board for Lending Solutions

Updated Category News Views 239

Algebrik AI Unveils New Advisory Board for Future Lending Algebrik AI Inc., a pioneering company in cloud-native and AI-powered loan origination, has announced the establishment of its inaugural Advisory Board. This dynamic group consists of influential leaders from credit unions, dedicated to guiding Algebrik AI as it seeks to redefine the lending sector through...

Continue Reading
Fed Set to Lower Rates: What this Means for the Economy

Updated Category News Views 338

Anticipating Changes from the Federal Reserve As the Federal Reserve's meeting approaches, there's a strong feeling that the Fed will cut interest rates for the first time in over four years. This action comes as the Fed looks to ease the tight economic conditions that were previously put in place to tackle high inflation. The big question now is whether they will choose...

Continue Reading
Investors Urged to Join Visa Inc. Class Action Lawsuit Now

Updated Category News Views 88

Join the Class Action Against Visa Inc. Today Investors who have suffered significant losses related to Visa Inc. (NYSE: V) should consider contacting Robbins LLP for legal guidance. A recent class action has been initiated on behalf of all individuals and entities who purchased or acquired Visa securities during a specific timeframe. This large-scale lawsuit illustrates...

Continue Reading
Freight Technologies Partners with Salzillo for Enhanced TMS Solutions

Updated Category News Views 82

Freight Technologies and Salzillo Collaborate for Improved Logistics Freight Technologies, Inc. (NASDAQ: FRGT), affectionately known as "Fr8Tech," is making remarkable strides in the logistics sector by forming a strategic alliance with Salzillo, a well-respected name in freight transportation. This partnership aims to license Fr8Tech's Fleet Rocket Transportation...

Continue Reading